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S340 Poster Session IIcyclophosphamide 60 mg/kg/day D-6 to -5, and 14.4Gy total body
irradiation in 8 fractions D–3 to 0, with 20mg alemtuzumab added
to the bag in vitro, and cyclosporin as GVHD prophylaxis.
Median follow-up for surviving patients was 52 months. All pa-
tients engrafted, at a median of 11 days for neutrophils and 10 days
for platelets. Acute GvHD grade II-IV occurred in 16% (3/9 grade
.II) and extensive chronic GvHD in 27%, which was cutaneous
only in 10/13, and responded to prolonged cyclosporin alone or
short course systemic corticosteroid. Non-relapse mortality
(NRM)was 23% at 5 years, and estimated relapse risk 26%at 5 years.
Estimated event-free survival (EFS) was 54% at 5 years. Complete
remission at the time of transplant and the presence of any chronic
GVHD favourably impacted EFS, with HLA mismatching confer-
ring no disadvantage.
Use of this regimen therefore permits the successful transplanta-
tion of patients with high-risk disease using unrelated donors, with
no negative impact of HLA-mismatching at one and two loci (12
and 9 patients respectively), minimal acute GvHD, a modest rate
of chronicGVHDwhich was largely confined to skin and was readily
treatment-responsive, and no evidence of an excessive relapse rate.
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IMPACT OF A LOWER BUSULFAN AREA UNDER THE CONCENTRATION-
TIME CURVE (AUC) DOSING TARGET ON ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) OUTCOMES
CruzChacon, A.M.1, Perkins, J.B.1, Pidala, J.A.1, Kim, J.2, Yue, B.2,
Field, T.1, Anasetti, C.1 1Moffitt Cancer Center, Tampa, FL; 2Moffitt
Cancer Center, Tampa, FL
Busulfan systemic exposure, as measured pharmacokinetically by
area under the concentration-time curve (AUC), has been correlated
with transplant-related toxicity and efficacy. Attempting to reduce
morbidity and mortality in patients (pts) 60 years (yrs) or older
and/or those with significant comorbidity, we have pharmacokineti-
cally-targeted a lower daily busulfan AUC of 3500 mmol x min/L
compared to 5300 used in other pts. To evaluate the effectiveness
of this strategy, we retrospectively compared outcomes in 345 con-
secutive pts with hematologic malignancies receiving busulfan and
fludarabine from 7/04-10/09. 44 pts were targeted to busulfan
AUC of 3500 and were more likely to receive a matched unrelated
graft (p 5 0.038), have CLL, indolent NHL, or MDS (p\0.0001)
and a high risk of relapse as defined by CIBMTR criteria
(p\0.0001) compared to the AUC 5300 cohort. The median age
was 62 yrs for the AUC 3500 pts and 48 yrs for AUC 5300 pts
(p\0.0001). There were no significant differences in CMV serology,
HCT-CI scores, Karnofsky performance status (KPS), or history of
prior transplant. When adjusted for CMV serology, donor, diagno-
sis, HCT-CI, KPS, and age, busulfan AUCwas not a significant pre-
dictor of overall survival or cumulative incidence of nonrelapse
mortality. However, busulfan was an independent factor in a multi-
variable model for relapse-free survival (RFS) (HR 1.67; 95% CI
1.13-2.48) and of borderline significance in a multivariable model
of cumulative incidence of relapse (HR 1.7; 95%CI 0.98-2.93).
The 2-year estimate of RFS in the AUC 3500 pts was 21.9% vs
44.1% in the AUC 5300 pts. The cumulative incidence of relapse
at 2 years in the AUC 3500 was 41% vs. 31% in the AUC 5300
pts. This would suggest that careful consideration should be made
in choosing to reduce busulfan AUC as a reduction in intensity
may lead to reduced efficacy. These results should be interpreted
with caution due to the limitations of multivariable analysis of retro-
spective data as other patient characteristics may exist that cannot be
accounted for in this type of analysis.
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FLUDARABINE BASED PREPARATIVE REGIMEN CAN SECURE A SECOND
HEMATOPOIETIC STEM CELL TRANSPLANT AFTER INITIAL GRAFT REJEC-
TION
Tamari, R.1, Boulad, F.2, Papadopoulos, E.B.1, Kernan, N.A.2,
Jakubowski, A.1, Small, T.N.2, Perales, M.A.1, O’Reilly, R.J.2,
Young, J.W.1, Giralt, S.1, Barker, J.1, Castro Malaspina, H.1 1Memorial
Sloan Kettering Cancer Center, New York, NY; 2Memorial Sloan Ketter-
ing Cancer Center, New York, NY
Graft rejection after allogeneic stem cell transplantation (HSCT)
is a rare but often fatal complication.The optimal preparative regi-men for engraftment of a second transplant has not been well de-
fined. We previously described our experience in HSCT-2 for
graft rejection in 16 pts, we report here a larger series.
Patients&Methods:From1997- 2010, 24 pts underwent aHSCT-
2 for graft rejection. Median age was 19.8 years (range: 1- 61). All pts
were conditioned for HSCT-1 with myeloablative preparative regi-
men (TBI or busulfan-based) for acute chronic leukemia (N5 11/2),
MDS (N5 7) or congenital hematopoietic non-malignant disorders
(N 5 4). 20 of the first transplants were TCD. The donors for the
first transplant were: HLA matched related/unrelated (N 5 4/6),
HLA mismatched related/unrelated (N 5 3/11).The preparative
regimen for the second transplant consisted of Fludarabine (Flu)
(30 mg/m2/d/5 days) plus Cyclophosphamide (Cy) (60 mg/kg/d/2
days) (N 5 13), Flu (25 mg/m2d/ 5 days) plus Thiotepa (5 mg/kg/
d/2 days) (N 5 5), Cy (60 mg/kg/d/2 days) plus Thiotepa (5 mg/
kg/d/2 days) (N 5 3), Flu (30 mg/m2d/5 days) (N 5 2), Cy plus
low dose TBI (N 5 1). Thus, 19 of the 24 pts (79%) were condi-
tioned for HSCT-2 with a Flu based regimen. Pts also received
ATG (N 5 19) or Campath (N 5 5). The donors for HSCT-2
were: HLA-matched related/unrelated (N5 4/3), HLAmismatched
related/unrelated (N 5 10/7). The original donor was used in 8/24
cases. The grafts administrated were unmodified PBSCT (N 5 8),
unmodified BMT(N 5 2) or TCD PBSCT (N 5 14). The median
CD34/kg infused in the second transplant was 11.8x106CD34/kg
(2.8-34x106CD34/kg).
Results:All pts engrafted with a median of 13 (9-26) days; full donor
engraftment was documented in 21 (88%) pts. GVHD developed in
8 (33%) pts (aGvHD-7, cGvHD-1), 3 had received a TCD graft and
5 an unmodified graft. CMV and EBV reactivations occurred in 6
(25%) patients with 2 cases of EBV-LPD and 1 case of CMV pneu-
monitis. The preparative regimen for the second transplant was well
tolerated with minimal mucositis, and only one serious adverse
event: veno-occlusive disease. Twelve pts (50%) are alive with a me-
dian follow up time of 9.75 years (1.75-13.5 years); 9 pts (64%) re-
ceived a TCD transplant and 3 pts (30%) an unmodified transplant.
Conclusion: In this cohort of pts who underwent a HSCT-2, either
unmodified or TCD, Flu based chemotherapy conditioning was able
to assure engraftment with a relatively low toxicity profile and long
term survival.
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OUTCOMES OF SECOND TRANSPLANTS FOR DISEASE RECURRENCE OR
FOR MYELODYSPLASIA (MDS) DEVELOPING AFTER AN INITIAL TRANS-
PLANT (Tx)
Naik, S., D’Agostino, R. Jr., Lamar, Z., Graham, R.M., Vatca, M.,
Agnew, E., Higgins, A., Levitan, D., Hurd, D.Wake Forest Baptist Med-
ical center, Winston-Salem, NC
Introduction: Treatment options for persons who relapse after an
initial transplant (autologous [AutoTx] or allogeneic [AlloTx]) or
who develop MDS following an AutoTx are limited. Current treat-
ment options include chemotherapy, donor leukocyte infusions
(DLI) (if alloTx) and a second transplant. A second transplant may
be effective salvage therapy in some patients (pts) who relapse or
who develop MDS after their initial Tx if an allo donor can be
identified.
Methods: A total of 1808 transplants were performed at Wake For-
est Baptist Hospital from May 1990 through July 2011 and 1525 Tx
(84%) were performed for diagnosis of a hematological malignancy.
Of these, 52 pts (3%) received a second Tx for disease recurrence or
therapy relatedMDS.The diagnosis at the time of first transplant in-
cluded acute and chronic leukemia (n 5 15); lymphoma (n 5 16);
myeloma (n 5 16); MDS: MF (n 5 4(3:1)); germ cell tumor (n 5
1). An additional 7 pts who received second transplant were excluded
from analysis (1: aplastic anemia pt; 5 for planned tandem AutoTx;
one for insufficient data. Transplants were either Auto / Auto
(for relapse; n 5 12); Allo/ Allo (for relapse; n 5 9); or Auto/
Allo (for relapse or the development of MDS; n 5 31).
Results: Patient characteristics are presented in Table 1.PB (pe-
ripheral blood) was the most common graft type in 43 pts (n5 83%).
Median time to second transplant was 1.8 years (0.27-18 yrs). Total
body irradiation (TBI) was given in 17 % (n 5 9) pts during first
transplant and 6 % (n 5 3) pts during second transplant. Reduc-
ed-intensity regimen (Flu/Bu) was used in 42 % (n 5 22) pts and
myeloablative Bu/Cy regimen in 25 % (n 5 13) pts during second
